Trial Details

TERMINATED
Basic Information
Clinical ID c1641
Identifier NCT03616821
Trial Title Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis|IBD
Interventions DRUG: Brazikumab|DRUG: Placebo
Participant Information
Sponsor AstraZeneca
City Phoenix
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE2
Time Information
Start Date 2018-08-07
Primary Completion Date 2023-10-23
Completion Date 2023-10-23